ArticleJournal of the American Heart Association2025
DNA Methylation Algorithms of Aging and Incident Cardiovascular Disease: A Prospective Cohort Study.
Article in Journal of the American Heart Association, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Sensory impairment, epigenetic ageing, and later-life functional decline and mortality in older adults.GeroScience · 2026Article
- [Application of biological age for cardiovascular risk prediction in a community-based Chinese cohort].Beijing da xue xue bao. Yi xue ban = Journal of Peking University. Health sciences · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundWhile DNA methylation (DNAm)-based algorithms of aging show promise for predicting age-related diseases, their comparative utility for incident cardiovascular disease (CVD) remains underexplored. We aimed to systematically compare 13 DNAm algorithms in relation to CVD risk in older adults.
methodsThis prospective cohort study included 2112 participants from the US HRS (Health and Retirement Study) with baseline DNAm data (2016) and 6-year follow-up. DNAm profiling was performed using the Infinium MethylationEPIC BeadChip kit (EPIC, Illumina, San Diego, CA). Thirteen widely used DNAm algorithms of aging were evaluated. Cox proportional hazards models were used to estimate hazard ratios (HRs) and 95% CIs per 1-SD increase in risk scores for incident CVD, including any CVD, congestive heart failure, and stroke.
resultsDuring a median of 37 months' follow-up, a total of 288 CVD cases (congestive heart failure, 38; stroke, 152) were observed. Zhang_DNAmAge, methylation Pace of Aging, and DNAmGrimAgeAcc showed positive associations with any CVD risk, with HRs per SD increase of 1.25 (95% CI, 1.07-1.45), 1.16 (95% CI, 1.02-1.33), and 1.24 (95% CI, 1.05-1.47), respectively. For specific CVD subtypes, DNAmGrimAge was associated with congestive heart failure risk (HR, 1.47 [95% CI, 1.11-1.95]), while both mPoA (HR, 1.24 [95% CI, 1.03-1.49]) and HorvathAcc (HR, 1.28 [95% CI, 1.07-1.55]) predicted incident stroke. Significant dose-response relationships (
conclusionsZhang_DNAmAge, methylation Pace of Aging, and DNAmGrimAgeAcc function as independent predictors of incident CVD. These epigenetic biomarkers may improve early CVD detection and risk stratification in aging populations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.